|
|||||
|
|
Evaluation of urinary prostate cancer antigen‐3 (PCA3) and TMPRSS2‐ERG score changes when starting androgen‐deprivation therapy with triptorelin 6‐month formulation in patients with locally advanced and metastatic prostate cancer |
|
| Authors: | Luis Martínez‐Piñeiro Jack A. Schalken Patrick Cabri Pascal Maisonobe Alexandre de la Taille Triptocare Study Group |
| Affiliation: | 1. Urology Unit, Infanta Sofía University Hospital, , Madrid, Spain;2. Department of Urology, Radboud University Nijmegen Medical Centre, , Nijmegen, The Netherlands;3. Ipsen Pharma, , Paris, France;4. Department of Urology, CHU Mondor, , Créteil, France |
| Abstract: | |
| Keywords: | advanced prostate cancer disease severity GnRH agonist PCA3 TMPRSS2‐ERG |